FDA Streamlines Drug Testing Regulations to Embrace Advanced, Non-Animal Methods

The U.S. Food and Drug Administration (FDA) has updated its regulations, as announced by the agency, to officially recognize and encourage the use of non-animal testing methods in the development of drugs and biological products for human use. This regulatory adjustment aims to integrate scientific advancements that offer alternatives to traditional animal studies, while still upholding existing safety standards crucial for human drug development.

The updated rule reflects the significant progress in scientific and technological fields, which have introduced a wider array of testing options. These innovative methods include the use of human cells, sophisticated organ-on-a-chip technology, advanced computer modeling, and other cutting-edge techniques. The FDA’s intention is to provide scientists and drug developers with enhanced flexibility to select the most scientifically appropriate testing approach for their specific research questions. The agency emphasizes that the goal is not to replace one rigid methodology with another, but rather to support rigorous, modern science, which includes continuing to utilize animal studies when they remain appropriate and validated, alongside alternative methods when they can sufficiently provide the necessary evidence to safeguard patients.

Key changes in the regulation involve replacing specific terminology. Phrases such as “animal tests” and “animal studies” are now being substituted with “nonclinical tests” and “nonclinical studies.” This update also redefines related terms, including “preclinical” and “in vitro,” aligning them with the Food and Drug Omnibus Reform Act of 2022 (FDORA). This federal law acknowledges that both novel non-animal methods and traditional animal studies can serve as valid sources of evidence to support the initiation of human trials. The rule explicitly removes language that might imply animal testing is the sole acceptable means of gathering safety data for regulatory approval of products intended for human use. It is important to note that the updated regulation does not eliminate or prohibit animal studies, nor does it alter existing evidentiary standards or introduce new costs or requirements for drug developers.

To further facilitate the adoption of these new approaches, the FDA has launched a database showcasing specific applications of New Approach Methodologies (NAMs). This initial release features 25 examples drawn from publicly accessible FDA review materials, demonstrating the practical implementation of these innovative methods. These actions are part of a broader initiative by the Department of Health and Human Services, including the FDA, to advance drug development through NAMs. Such methods are recognized for their potential to provide a more accurate reflection of human biology. Developers are now encouraged to use NAMs for generating safety information, provided these methods are adequately validated and suitable for the specific product and regulatory inquiry.

These regulatory updates align with Pillar 1—Innovation and Global Leadership—of the FDA’s Public Health Pillars. By formally acknowledging a broader spectrum of scientific methodologies, the FDA is keeping pace with technological advancements and reinforcing its leadership in regulatory science. The promotion of NAMs also complements Operation TrialBlazer, a Department of Health and Human Services initiative aimed at modernizing clinical research and expediting the development of life-saving treatments. The establishment of clearer terminology and regulatory expectations is intended to reduce uncertainty for sponsors as they develop nonclinical evidence and prepare applications for clinical trials. The agency is currently inviting public comment on this rule, encouraging input from clinicians, patients, caregivers, the scientific community, industry stakeholders, and other interested parties. Information on how to submit comments can be found in the Federal Register notices for the direct final rule, the companion proposed rule, and the comment period. If the FDA receives significant adverse comments on the direct final rule, it will be withdrawn, and the rulemaking process will continue through the standard notice-and-comment procedures utilizing the proposed rule. Publishing both simultaneously is designed to ensure the rulemaking process can proceed efficiently regardless of the feedback received.

Article by Mel Anara, based upon information from the U.S. Food and Drug Administration.

Video Spotlight